Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals (ZNTL) has announced the granting of inducement stock options to three newly hired employees on April 1, 2025. The Compensation Committee approved non-qualified stock options to purchase 140,000 shares of common stock under the company's 2022 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $1.39 per share, matching the closing price of Zentalis' stock on The Nasdaq Global Market on the grant date. These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting in monthly installments over the following three years, subject to continued employment.
Zentalis Pharmaceuticals (ZNTL) ha annunciato l'assegnazione di opzioni azionarie di incentivazione a tre nuovi dipendenti assunti il 1° aprile 2025. Il Comitato per la Compensazione ha approvato opzioni azionarie non qualificate per l'acquisto di 140.000 azioni ordinarie nell'ambito del Piano di Incentivazione per l'Occupazione 2022 dell'azienda.
Le opzioni azionarie sono state concesse a un prezzo di esercizio di $1.39 per azione, corrispondente al prezzo di chiusura delle azioni di Zentalis sul Nasdaq Global Market alla data di concessione. Queste opzioni hanno un termine di 10 anni e verranno maturate in quattro anni, con il 25% che matura dopo il primo anno e il restante 75% che matura in rate mensili nei successivi tre anni, a condizione di continuare l'impiego.
Zentalis Pharmaceuticals (ZNTL) ha anunciado la concesión de opciones sobre acciones de incentivo a tres nuevos empleados contratados el 1 de abril de 2025. El Comité de Compensación aprobó opciones sobre acciones no calificadas para comprar 140,000 acciones ordinarias bajo el Plan de Incentivo de Empleo 2022 de la empresa.
Las opciones sobre acciones se otorgaron a un precio de ejercicio de $1.39 por acción, igualando el precio de cierre de las acciones de Zentalis en el Nasdaq Global Market en la fecha de concesión. Estas opciones tienen un plazo de 10 años y se consolidarán durante cuatro años, con el 25% consolidándose después del primer año y el 75% restante consolidándose en cuotas mensuales durante los tres años siguientes, sujeto a la continuación del empleo.
젠탈리스 제약(ZNTL)은 2025년 4월 1일에 새로 고용된 세 명의 직원에게 유인 주식 옵션을 부여한다고 발표했습니다. 보상 위원회는 회사의 2022 고용 유인 인센티브 수여 계획에 따라 140,000주를 구매할 수 있는 비자격 주식 옵션을 승인했습니다.
주식 옵션은 주당 $1.39의 행사 가격으로 부여되었으며, 이는 부여일에 젠탈리스 주식이 나스닥 글로벌 마켓에서 마감된 가격과 일치합니다. 이 옵션은 10년의 기간을 가지며, 4년에 걸쳐 분할되어 1년 후에 25%가 확정되고, 나머지 75%는 다음 3년 동안 월별로 확정됩니다. 계속 고용되는 조건이 있습니다.
Zentalis Pharmaceuticals (ZNTL) a annoncé l'octroi d'options d'achat d'actions d'incitation à trois nouveaux employés embauchés le 1er avril 2025. Le Comité de Rémunération a approuvé des options d'achat d'actions non qualifiées pour l'achat de 140 000 actions ordinaires dans le cadre du Plan d'Incitation à l'Emploi 2022 de la société.
Les options d'achat d'actions ont été accordées à un prix d'exercice de 1,39 $ par action, correspondant au prix de clôture de l'action de Zentalis sur le Nasdaq Global Market à la date d'octroi. Ces options ont une durée de 10 ans et seront acquises sur une période de quatre ans, avec 25 % acquises après la première année et les 75 % restants acquises par versements mensuels au cours des trois années suivantes, sous réserve de l'emploi continu.
Zentalis Pharmaceuticals (ZNTL) hat die Gewährung von Anreiz-Aktienoptionen an drei neu eingestellte Mitarbeiter am 1. April 2025 bekannt gegeben. Der Vergütungsausschuss genehmigte nicht qualifizierte Aktienoptionen zum Kauf von 140.000 Stammaktien im Rahmen des Unternehmensplans zur Anreizgewährung für die Beschäftigung 2022.
Die Aktienoptionen wurden zu einem Ausübungspreis von $1,39 pro Aktie gewährt, was dem Schlusskurs der Zentalis-Aktie am Nasdaq Global Market am Tag der Gewährung entspricht. Diese Optionen haben eine Laufzeit von 10 Jahren und werden über vier Jahre hinweg fällig, wobei 25 % nach dem ersten Jahr und die verbleibenden 75 % in monatlichen Raten über die folgenden drei Jahre fällig werden, vorbehaltlich der fortgesetzten Beschäftigung.
- Stock-based compensation aligns new employee interests with shareholders
- Potential shareholder dilution from 140,000 new shares
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on April 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 140,000 shares of the Company’s common stock to three (3) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
Vesting of the stock options is subject to the employees’ continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
Contacts:
Haibo Wang – Chief Business Officer
Ron Moldaver – Investor Relations
ir@zentalis.com
FAQ
What are the vesting terms for ZNTL's April 2025 inducement stock options?
How many shares were granted in Zentalis' April 2025 inducement stock options?
What is the exercise price for ZNTL's April 2025 inducement grants?
How long is the term of ZNTL's April 2025 inducement stock options?
